Clinical trial

Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients

NCT04616456

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-12-30

PhaseEARLY_PHASE1

Study timeline

Study start (actual)2020-12-30Date precision: day

Registry last updated2022-08-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple System Atrophyunresolved

Multiple System Atrophy, Cerebellar Variantunresolved

Multiple System Atrophy, Parkinson Variant (Disorder)unresolved

Multiple System Atrophy (MSA) With Orthostatic Hypotensionunresolved

Interventions

[F-18]PBR06DRUG

VerdiperstatDRUG

Sponsors & collaborators

Brigham and Women's Hospitallead sponsor

Biohaven Pharmaceuticals, Inc.collaborator

Mapped research locations

BostonMassachusetts, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04616456 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.